New Machine Learning Models Improve Prediction of Thrombosis and Bleeding in Cancer – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Danielle Carole Roy et al, adding:
”Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer (AVERT trial analysis)
Using data from 514 ambulatory cancer patients in the AVERT trial, machine-learning models combining biomarkers and genetics predicted both venous thromboembolism (AUC 0.92) and clinically relevant bleeding (AUC 0.90).
VTE risk tracked with factor V Leiden and certain cancers, while bleeding risk tracked with cardiac and inflammatory markers.
The sample stayed modest.
Title: Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial
Authors: Danielle Carole Roy, Tzu-Fei Wang, Philip Wells, Ranjeeta Mallick, Dylan Burger, Marc Carrier, Steven Hawken

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering